Department of Clinical Medicine, Dow Medical College, Karachi 74200, Pakistan.
Department of Nursing & Midwifery Research, Hamad Medical Corporation, Doha 3050, Qatar.
World J Gastroenterol. 2024 Sep 28;30(36):4021-4024. doi: 10.3748/wjg.v30.i36.4021.
Hemorrhoids are a common and painful condition, with conventional treatments such as endoscopic rubber band ligation (ERBL) and injection sclerotherapy often falling short due to high recurrence rates and significant post-operative pain. A clinical trial by Qu introduces a novel approach called endoscopic poli-docanol foam sclerobanding (EFSB). This multicenter randomized trial involved 195 patients with grade II and III internal hemorrhoids and demonstrated that EFSB significantly reduced recurrence rates and post-procedural pain while improving symptom relief and patient satisfaction compared to ERBL. The study's strengths include its robust design, comprehensive outcome evaluation, and patient-centered approach. Despite limitations such as the single-blind design and relatively short follow-up period, the findings suggest that EFSB could enhance clinical practice by offering a more effective and patient-friendly treatment option. Further research is needed to validate these results and explore the long-term benefits and cost-effectiveness of EFSB.
痔疮是一种常见且疼痛的疾病，传统的治疗方法，如内镜橡皮圈结扎术（ERBL）和硬化注射疗法，由于高复发率和显著的术后疼痛，往往效果不佳。Qu 等人的一项临床试验引入了一种名为内镜聚多卡醇泡沫硬化套扎术（EFSB）的新方法。这项多中心随机试验纳入了 195 例 II 级和 III 级内痔患者，结果表明与 ERBL 相比，EFSB 可显著降低复发率和术后疼痛，同时改善症状缓解和患者满意度。该研究的优势包括其稳健的设计、全面的结果评估和以患者为中心的方法。尽管存在一些局限性，如单盲设计和相对较短的随访期，但这些发现表明 EFSB 通过提供更有效和患者友好的治疗选择，可以增强临床实践。需要进一步的研究来验证这些结果，并探讨 EFSB 的长期获益和成本效益。
